What biomarker testing is recommended for early stage Melanoma

Biomarker Testing for Early-Stage Melanoma

Based on the NCCN Guidelines for Patients: Melanoma (2025), here's what you should know about biomarker testing in early-stage melanoma:

What Testing is Recommended

According to the NCCN Guidelines, biomarker testing for early-stage melanoma (stages 0-2) is limited. The guidelines indicate that:

• BRAF mutation testing is NOT routinely recommended for early-stage disease at diagnosis
• Testing focuses primarily on pathologic features of the tumor itself rather than molecular biomarkers

Why This Matters

Early-stage melanomas are typically treated with surgery alone, which is often curative. Since systemic therapies (drugs that treat cancer throughout the body) aren't usually part of early-stage treatment, the biomarkers that guide those drug choices aren't needed at this stage.

When Biomarker Testing Becomes Important

Biomarker testing becomes relevant if:

• Your melanoma recurs (comes back)
• Your cancer is found to be stage 3 or higher at the time of surgery
• Your doctor is considering systemic therapy options

In these situations, BRAF V600 mutation testing becomes important because it can guide treatment decisions for targeted therapies like dabrafenib/trametinib.

Questions to Ask Your Oncologist

1. Based on my pathology report, do I need any biomarker testing?
2. If my melanoma recurs, what testing would be done?
3. Are there any genetic testing recommendations for my family members?

According to the NCCN Guidelines for Patients: Melanoma, early-stage melanoma management emphasizes complete surgical excision with appropriate margins rather than biomarker-driven treatment decisions.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.